Journal article
Successful Discontinuation of Eculizumab in a Pediatric Patient With Atypical Hemolytic Uremic Syndrome and Underlying Systematic Lupus Erythematosus
Curēus (Palo Alto, CA), Vol.14(5)
05/18/2022
DOI: 10.7759/cureus.25117
PMCID: PMC9205680
PMID: 35733457
Abstract
Although rare, atypical hemolytic syndrome (aHUS) has been recognized as one of the direst complications of systemic lupus erythematosus (SLE). Furthermore, the diagnosis of coexisting aHUS and SLE is a diagnostic dilemma with similar clinical characteristics between both entities. Eculizumab is an effective treatment for complement-mediated atypical hemolytic uremic syndrome, but much is still to be learned about optimal treatment duration and if eculizumab can be discontinued without thrombotic microangiopathy reoccurrence. Here, we report a pediatric case of severe SLE complicated by aHUS that responded favorably to eculizumab, followed by successful discontinuation without recurrence of aHUS despite having numerous identified risk factors.
Details
- Title: Subtitle
- Successful Discontinuation of Eculizumab in a Pediatric Patient With Atypical Hemolytic Uremic Syndrome and Underlying Systematic Lupus Erythematosus
- Creators
- Issa Alhamoud - Univ Iowa, Pediat Nephrol, Iowa City, IA 52242 USASydney A. Freiberg - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Curēus (Palo Alto, CA), Vol.14(5)
- Publisher
- Cureus Inc
- DOI
- 10.7759/cureus.25117
- PMID
- 35733457
- PMCID
- PMC9205680
- ISSN
- 2168-8184
- eISSN
- 2168-8184
- Number of pages
- 5
- Language
- English
- Date published
- 05/18/2022
- Academic Unit
- Stead Family Department of Pediatrics; Internal Medicine
- Record Identifier
- 9984354517502771
Metrics
10 Record Views